INTERVIEWS

Dr. Carlos Doti discusses the results from two trials – Ph.2 ACE-CL-001 and Ph.3 ASCEND, that was presented at the virtual edition of the European Hematology Association‘s (EHA25) Annual Congress, showing long-term efficacy and tolerability of CALQUENCE® (acalabrutinib) in patients with chronic lymphocytic leukemia (CLL).

Dr. Imamu Tomlinson, CEO of Vituity and a practicing emergency physician, discusses his own experience with discrimination as a Black American and how it has influenced his approach to leadership and medicine.  He talks about conversations he has had with his physician teams about racial injustice, the role of healthcare in serving as an equalizer, and the impact healthcare access can have on bringing justice to local communities.

Linda Hand, CEO of Prealize, discusses the use of AI and machine learning to pinpoint individuals and populations most likely to have a significant health event over the next 12-18 months that will benefit from early intervention. She also talks about the post-pandemic healthcare surge and precision public health.

Dr. Cedric Bryant, Ph.D., Chief Science Officer at the American Council on Exercise (ACE) discusses ACE’s behavior change research-based philosophy called the Mover Method™ which ACE believes can have a measurable impact on public health. He also talks about health equity and how some of ACE’s exercise professionals work and live in communities where lifestyle-related diseases like diabetes/heart disease are most prevalent and he is working with organizations like the World Health Organization and the CDC to find solutions for these lifestyle diseases. 

Dr. Roy Herbst, MD, of Yale Cancer Center and Smilow Cancer Hospital, discusses data presented at the American Society of Clinical Oncology (ASCO20) Virtual Scientific Program highlighting some of the latest research in non-small cell lung cancer (NSCLC) the most common type of lung cancer.

Oswald Peterson, diagnosed in early 2017 with stage 4 non-small cell lung cancer that had spread throughout his body shares his story and talks about the immunotherapy treatments, pembrolizumab (KEYTRUDA®) that shrank his cancer and extended his life.  He is an ImmunoAdvocate with the Cancer Research Institute and is passionate about raising awareness around immunotherapy research. 

Dr. Steve Shak, Chief Medical Officer at Exact Sciences discusses the publication of new analyses of two clinical studies that demonstrate for the first time the value of the Oncotype DX Genomic Prostate Score® (GPS™) test in guiding treatment plans in patients with unfavorable intermediate (UFI)-risk prostate cancer. The study, published in “Urology”, validates the GPS test as a strong independent predictor of critical endpoints in UFI-risk prostate cancer patients, suggesting its benefit in personalizing and improving treatment decisions. 

Dr. Thomas Jones, MD, Director of the Cardiac Catheterization Laboratories at Seattle Children’s Hospital discusses congenital heart disease and the importance for this patient population to “stay in care” during the COVID-19 pandemic.  He also discusses late-breaking data that was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 on the Medtronic Melody™ transcatheter pulmonary valve 10-year study results.

Tom Koulopoulos, Chairman and Founder of Delphi Group, discusses his new book “Reimagining Healthcare: How the Smartsourcing Revolution Will Drive the Future of Healthcare and Refocus It on What Matters Most, the Patient” (Post Hill Press, May 26, 2020)

Cyrus Cooper, president of the International Osteoporosis Foundation (IOF) and professor of Musculoskeletal Science at the University of Oxford, discusses IOF’s Capture the Fracture® initiative in partnership with Amgen, UCB, and the University of Oxford.  This initiative aims to reduce osteoporosis-related hip and vertebral fractures by 25 percent by 2025, the partners aim to double the 390 existing Capture the Fracture® programs known as Fracture Liaison Services (FLS) by the end of 2022.  Osteoporosis affects more than 200 million people worldwide with more than 8.9 million fractures reported in a single year.